clinical trial · NCT06624228
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
UCB Biopharma SRL·phase3·completed·n = 553
Psoriatic ArthritisBimekizumabRisankizumabPlacebo
brief summary
The purpose of the study is to compare the efficacy of bimekizumab versus risankizumab after 16 weeks of treatment in study participants with active psoriatic arthritis (PsA).
started
Oct 21, 2024
primary completion
Feb 6, 2026
completion
Jun 3, 2026
last updated
Sep 2, 2026
official title
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol